cilengitide has been researched along with fluorouracil in 1 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (fluorouracil) | Trials (fluorouracil) | Recent Studies (post-2010) (fluorouracil) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 45,562 | 9,307 | 14,663 |
| Protein | Taxonomy | cilengitide (IC50) | fluorouracil (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.32 | |
| Thymidylate synthase | Mus musculus (house mouse) | 1.58 | |
| Aromatase | Homo sapiens (human) | 0.63 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bethe, U; Brümmendorf, TH; Clement, PM; Delord, JP; Erfán, J; Gauler, TC; Hicking, C; Iglesias, L; Keilholz, U; Krauss, J; Mesía, R; Peyrade, F; Remenar, E; Schafhausen, P; Vermorken, JB | 1 |
1 trial(s) available for cilengitide and fluorouracil
| Article | Year |
|---|---|
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Snake Venoms; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |